(Q69350403)

English

Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets

scientific article published on 01 January 1989

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

1 reference

based on heuristic

inferred from title

author name string

S C Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

L Owen-Schaub

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

E A Grimm

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

J A Roth

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

publication date

1 January 1989

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

193-198

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2543502%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

https://scigraph.springernature.com/pub.10.1007/bf00199995

0 references

Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Projections of lung cancer mortality in the United States: 1985-2025.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification and expression of the c-myc oncogene in human lung cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Augmentation of cell-mediated cytotoxicity against renal carcinoma cells by recombinant interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysis of human solid tumor cells by lymphokine-activated natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2543502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q69350403&oldid=1966787885"